insulin detemir · Levemir

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

Also approved (2)
JP
  • Treatment of diabetes mellitus in cases where insulin therapy is indicated
Product first approved 2011PMDA
EU
  • Diabetes mellitus (Levemir, Novo Nordisk A/S); EMA page still lists it as authorised
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (37)
Type 1 Diabetes
NCT01831765 · Novo Nordisk A/S
2013-08-26 – 2015-06-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01513473 · Novo Nordisk A/S
2012-01-16 – 2013-07-30 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00474045 · Novo Nordisk A/S
2007-05 – 2010-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00623194 · Novo Nordisk A/S
2008-02 – 2009-09 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00435019 · Novo Nordisk A/S
2007-02 – 2008-09 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00447382 · Novo Nordisk A/S
2007-03 – 2008-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00322257 · Novo Nordisk A/S
2006-05-01 – 2008-04-02 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00095082 · Novo Nordisk A/S
2004-09 – 2005-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00184639 · Novo Nordisk A/S
2004-08-16 – 2005-11-22 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00605137 · Novo Nordisk A/S
2004-05-21 – 2005-04-23 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00595374 · Novo Nordisk A/S
2003-12-02 – 2004-10-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00312156 · Novo Nordisk A/S
2002-08 – 2003-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00312104 · Novo Nordisk A/S
2002-04 – 2003-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01697657 · Novo Nordisk A/S
2001-09 – 2002-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01486940 · Novo Nordisk A/S
2002-03 – 2002-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT03220425 · Novo Nordisk A/S
2001-02-01 – 2001-11-12 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT00184600 · Novo Nordisk A/S
2004-11 – 2009-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00789191 · Novo Nordisk A/S
2008-11 – 2009-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00331604 · Novo Nordisk A/S
2006-08-31 – 2008-05-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00383877 · Novo Nordisk A/S
2006-09 – 2007-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00504673 · Novo Nordisk A/S
2005-04 – 2006-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01709929 · Novo Nordisk A/S
2005-10 – 2006-04 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT00104182 · Novo Nordisk A/S
2005-02 – 2006-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00097084 · Novo Nordisk A/S
2004-09 – 2005-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00106366 · Novo Nordisk A/S
2005-03 – 2005-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00604253 · Novo Nordisk A/S
2003-12 – 2005-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00605020 · Novo Nordisk A/S
2003-12-02 – 2005-03-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00592527 · Novo Nordisk A/S
2004-04 – 2004-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT01100892 · Sydney Children's Hospitals Network
2010-12 – 2023-02 · Cystic Fibrosis, Diabetes
What this study did
NCT04222348 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
2016-10-26 – 2020-07-01 · Diabetes, Gestational, Perinatal Disorder, Puerperal Disorder
What this study did
NCT01461616 · University of Aarhus
2012-02 – 2012-11 · Diabetes Mellitus, Type 1
What this study did
NCT00604344 · Novo Nordisk A/S
2003-04 – 2005-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT00639626 · Nationwide Children's Hospital
2008-08 – 2010-05 · Cystic Fibrosis Related Diabetes
What this study did
Phase 2 (3)
Type 2 Diabetes
NCT05124457 · University of California, Los Angeles
2022-02-01 – 2025-06 · Gestational Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT01595646 · Wake Forest University Health Sciences
2011-11 – 2015-03-12 · Alzheimer's Disease, Mild Cognitive Impairment
What this study did
NCT01547169 · University of Washington
2011-03 – 2012-12 · Alzheimer's Disease, Mild Cognitive Impairment
What this study did
Phase 1 (13)
Type 1 Diabetes
NCT01497574 · Novo Nordisk A/S
2005-05 – 2005-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01542450 · Novo Nordisk A/S
2002-08 – 2003-02 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT00873223 · Novo Nordisk A/S
2009-03 – 2009-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01497600 · Novo Nordisk A/S
2004-02 – 2004-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01497561 · Novo Nordisk A/S
2003-03 – 2003-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT00810589 · Medical University of Graz
2008-11 – 2008-12 · Diabetes, Type I
What this study did
NCT01498939 · Novo Nordisk A/S
2007-08 – 2007-09 · Diabetes, Healthy
What this study did
NCT01490099 · Novo Nordisk A/S
2006-08 – 2006-11 · Diabetes, Healthy
What this study did
NCT01498926 · Novo Nordisk A/S
2005-11 – 2006-02 · Diabetes, Healthy
What this study did
NCT01497587 · Novo Nordisk A/S
2005-08 – 2005-12 · Diabetes, Healthy
What this study did
NCT00760448 · Novo Nordisk A/S
2004-04 – 2005-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01497535 · Novo Nordisk A/S
2004-05-27 – 2004-10-31 · Diabetes, Healthy
What this study did
NCT02162407 · Novo Nordisk A/S
1999-10 – 1999-12 · Diabetes, Healthy
What this study did
Phase 4 (37)
Type 1 Diabetes
NCT00346996 · Lise Tarnow
2007-05 – 2012-08 · Type 1 Diabetes
What this study did
NCT01440439 · Buckinghamshire Healthcare NHS Trust
2011-11 – 2012-06 · Diabetes Mellitus, Type 1
What this study did
NCT00564395 · Montefiore Medical Center
2007-08 – 2010-05 · Type 1 Diabetes Mellitus
What this study did
NCT00542399 · Rabin Medical Center
2007-11 – 2010-03 · Type 1 Diabetes Mellitus
What this study did
NCT00509925 · Novo Nordisk A/S
2007-07 – 2008-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00313742 · Novo Nordisk A/S
2006-04 – 2006-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00117780 · Novo Nordisk A/S
2005-06 – 2006-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT02048189 · Centre Hospitalier Universitaire Dijon
2012-03-08 – 2015-02-26 · Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy
What this study did
NCT00862875 · Institut de Recherches Cliniques de Montreal
2009-03 – 2014-04 · Type 2 Diabetes
What this study did
NCT01165684 · Novo Nordisk A/S
2010-10 – 2012-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01232491 · Novo Nordisk A/S
2010-10-29 – 2011-11-14 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01076842 · Novo Nordisk A/S
2008-04 – 2011-04 · Diabetes Type 2
What this study did
NCT00906529 · University of Texas Southwestern Medical Center
2009-05 – 2011-03 · Type 2 Diabetes
What this study did
NCT00795600 · Novo Nordisk A/S
2009-04 – 2010-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00909480 · Novo Nordisk A/S
2009-05 – 2010-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00699686 · University of Padova
2008-05 – 2010-03 · Type 2 Diabetes, Endothelial Dysfunction, Cardiovascular Disease
What this study did
NCT00998335 · University of Florida
2007-06 – 2010-02 · Type 2 Diabetes
What this study did
NCT00742976 · Copenhagen University Hospital, Rigshospitalet
2008-06 – 2009-12 · Diabetes Type 2, Weight Gain
What this study did
NCT00591227 · Rush University Medical Center
2008-05 – 2009-07 · Type 2 Diabetes Mellitus
What this study did
NCT00747409 · Munich Municipal Hospital
2004-07 – 2009-06 · Type 2 Diabetes Mellitus
What this study did
NCT00537303 · Novo Nordisk A/S
2007-10 – 2009-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00506662 · Novo Nordisk A/S
2007-07 – 2008-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00634842 · Novo Nordisk A/S
2008-02 – 2008-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00455858 · Novo Nordisk A/S
2007-11 – 2008-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00590226 · Emory University
2006-12 – 2008-04 · Type 2 Diabetes
What this study did
NCT00467649 · AstraZeneca
2007-05 – 2008-04 · Type 2 Diabetes Mellitus
What this study did
NCT00521690 · Novo Nordisk A/S
2006-12 – 2007-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00274274 · Novo Nordisk A/S
2005-09 – 2006-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00264901 · Novo Nordisk A/S
2005-10 – 2006-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT00607737 · Lise Tarnow
2008-01 – 2010-07 · Diabetes Mellitus
What this study did
NCT00941148 · ikfe-CRO GmbH
2008-04 – 2009-03 · Type 2 Diabetic Patients, Insufficient Metabolic Control, OAD Treatment
What this study did
NCT00542620 · Novo Nordisk A/S
2007-09 – 2009-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00490893 · University Hospital Tuebingen
2006-03 – 2006-12 · Diabetes Mellitus, Hypoglycemia
What this study did
NCT00566124 · University of Aarhus
2005-01 – 2005-05 · Diabetes
What this study did
Early phase / not applicable (9)
Type 1 Diabetes
NCT00626080 · Amsterdam UMC, location VUmc
2009-01 – 2011-12 · Type 1 Diabetes
What this study did
NCT00564018 · University of Texas Southwestern Medical Center
2006-09 – 2011-04 · Type 1 Diabetes
What this study did
NCT00659165 · University of New Mexico
2008-04 – 2011-01 · Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT01232946 · Indiana University
2012-01 – 2017-09-08 · Type 2 Diabetes
What this study did
NCT01281605 · Mackay Memorial Hospital
2011-01 – 2016-05 · Type 2 Diabetes
What this study did
NCT01837680 · St. Luke's-Roosevelt Hospital Center
2013-03 – 2015-03 · Diabetes, Gestational, Diabetes, Type 2
What this study did
NCT01420692 · Ankara University
2010-06 – 2012-06 · Type 2 Diabetes Mellitus
What this study did
NCT01377155 · Diabetes Care Center
2011-06 – 2011-12 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT01239550 · Vanderbilt University
2011-04 – 2028-12 · Diabetes, Obesity
What this study did
Used as active comparator (20)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (9)
Type 1 Diabetes
NCT03377699 · Novo Nordisk A/S
2017-11-22 – 2020-12-17 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01616784 · Sheffield Teaching Hospitals NHS Foundation Trust
2011-11 – 2015-11 · Type 1 Diabetes
What this study did
NCT01074268 · Novo Nordisk A/S
2010-02 – 2010-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00978627 · Novo Nordisk A/S
2009-08 – 2010-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00487240 · Eli Lilly and Company
2007-06 – 2008-08 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT01003184 · AstraZeneca
2009-10 – 2011-12 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT00271284 · Sanofi
2005-10 – 2008-09 · Diabetes Mellitus, Type 1
What this study did
Phase 2 (1)
Type 1 Diabetes
NCT00841087 · Novo Nordisk A/S
2009-01 – 2009-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 1 (4)
Type 1 Diabetes
NCT06685185 · Novo Nordisk A/S
2024-11-12 – 2026-03-18 · Diabetes Mellitus, Type 1
What this study did
NCT01135927 · Novo Nordisk A/S
2010-06 – 2010-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT01043510 · Novo Nordisk A/S
2010-01 – 2010-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 4 (5)
Type 2 Diabetes
NCT02451137 · Sanofi
2015-06-16 – 2018-08-09 · Diabetes Mellitus, Type 2
What this study did
NCT00657943 · Steno Diabetes Center Copenhagen
2008-04 – 2012-12 · Type 2 Diabetes, Atherosclerosis, Arteriosclerosis
What this study did
NCT00405418 · Sanofi
2006-11 – 2008-06 · Diabetes Mellitus, Type 2
What this study did
Early phase / not applicable (1)
Type 2 Diabetes
NCT01310452 · Fudan University
started 2011-01 · Type 2 Diabetes Mellitus
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Other / comorbidity
NCT02741687 · Emory University
2016-06 – 2017-04 · Hyperglycemia
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Detemir (Levemir): this drugApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Levemir (insulin detemir) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Early phase / not applicableDiabetes, ObesityActive not recruiting
Est. primary completion 2028-12 · NCT01239550 · CT.gov ↗
What to watch

See the full readout calendar ↗